Metastatic Spine Disease

Metastatic disease is the most common neoplasm of the spine, 90% of all spinal tumours, and it costs the patient through pain, neurological dysfunction and mechanical instability. Between 10 and 30% of cancer patients develop spinal metastases, and the spine is the most common site of skeletal metastasis.

Who sends them. Breast, prostate, lung, thyroid and kidney primaries account for 80% of cases; the card carries what matters about each.

Where. The distribution follows red marrow, which is why the thoracic spine carries most of the disease. Each region brings its own problems:

Within the vertebra. The vertebral body, the anterior column, is involved in 85% of lesions, the pedicles in 60% and the posterior elements in 40%. Isolated posterior element disease is under 5%.

The metastatic cascade. Reaching the spine takes six steps:

1. Local invasion - the primary tumour invades local vasculature
2. Intravasation - tumour cells enter the circulation
3. Survival - evading immune surveillance in the bloodstream
4. Extravasation - exit at distant sites, where Batson's plexus plays its part
5. Colonisation - a micrometastasis is established in the marrow
6. Angiogenesis - a blood supply develops for growth

Osteolytic metastases, the most common type, destroy bone through osteoclast activation: the tumour secretes PTHrP, IL-6 and IL-11. They appear as punched-out lesions with cortical destruction, cause rapid structural compromise, and the fracture risk is high once over 50% of the vertebral body is involved.

Osteoblastic (sclerotic) metastases lay down abnormal bone under TGF-beta, BMPs and endothelin-1, giving dense sclerotic lesions, the "ivory vertebra". Prostate cancer is 95% blastic and some breast cancers are too. Blastic lesions are relatively more stable, but a dense vertebra is still biomechanically abnormal.

Mixed lytic and blastic metastases show both destruction and formation, a variable tumour-bone interaction with heterogeneous density. Half of breast cancer metastases are mixed, and lung is another source. For stability they are treated as lytic.

By primary. Lesion type, vascularity, radiosensitivity and prognosis all travel with the histology:

SINS - Spinal Instability Neoplastic Score

SINS answers one question: is this spine mechanically stable? Six components are scored and summed to a maximum of 18 points.

Reading the total. The score sorts the spine into three bands, and the band tells you who needs to be in the room:

• 0-6, stable: no surgical consultation required; radiation alone if oncologically indicated
• 7-12, potentially unstable: surgical consultation recommended, and clinical judgement decides whether to stabilise
• 13-18, unstable: surgical stabilisation required

View larger

Bilsky Epidural Compression Scale

The epidural spinal cord compression (ESCC) scale grades what the epidural tumour is doing to the thecal sac and cord on the axial image, from bone-only disease to circumferential compression with no CSF left. What grade 1c means depends on histology: in a radiosensitive tumour it may be observed or treated with radiation alone, and the radioresistant case is the alert below.

View larger

View larger

NOMS Decision Framework

NOMS puts the four questions that decide treatment into one frame: Neurologic, Oncologic, Mechanical and Systemic. Each component independently influences the decision, and the answer comes from integrating all four rather than from any one of them.

Pain. Four patterns, each pointing somewhere different:

• Mechanical pain, worse with movement, suggests instability (SINS +3)
• Biological pain is night pain, constant and progressive, from tumour burden
• Radicular pain in a dermatomal distribution points to nerve root compression
• Myelopathic symptoms: gait difficulty and coordination problems

Red flags for metastatic disease. Any of these in a patient with back pain should raise the question:

• Age over 50 with new back pain
• Known cancer history, even remote
• Unexplained weight loss, over 10% in 6 months
• Night pain unrelieved by position
• Progressive neurological symptoms
• Pain unresponsive to conservative treatment

Neurological examination is essential:

• Motor: myotomal testing, with the Frankel/ASIA grade recorded
• Sensory: dermatomal assessment and a sensory level
• Reflexes: hyperreflexia (upper motor neurone) versus hyporeflexia (lower motor neurone)
• Long tract signs: Hoffman's, Babinski, clonus
• Gait: ambulatory status

The spine itself is examined for tenderness over the involved levels, a palpable step-off or deformity, and paraspinal muscle spasm.

MESCC. Metastatic epidural spinal cord compression develops in 5-10% of cancer patients. Neurological deterioration can be rapid, over hours to days, and time to treatment is what determines the neurological outcome.

Laboratory studies. The essential tests:

• CBC, CMP, LFTs (baseline, nutritional status)
• Calcium (hypercalcaemia is common in bone metastases)
• Tumour markers (PSA, CEA, CA 19-9, AFP)
• SPEP/UPEP (exclude myeloma)
• HIV (if unknown primary)

MRI is the gold standard, with a sensitivity of 98.5% and specificity of 98.9% for osseous metastases. The sequences are T1, T2, STIR and post-gadolinium, and the findings that make the diagnosis are:

• T1 hypointense (marrow replacement)
• T2 hyperintense (tumour/oedema)
• Gadolinium enhancement
• Epidural extension (Bilsky grading)

View larger

CT assesses the bone architecture and shows cortical destruction, guides the biopsy, and is the surgical planning study for pedicle trajectory.

View larger

View larger

Plain radiographs have limited sensitivity, because 30-50% of the bone must be lost before a lesion shows. They still assess alignment, and standing views give the sagittal balance.

Nuclear medicine. Bone scan is sensitive but non-specific; PET-CT stages the disease and measures treatment response; SPECT improves localisation.

Biopsy is indicated when the tissue diagnosis is in doubt:

• Unknown primary
• Solitary lesion (exclude a primary tumour)
• Atypical imaging features
• No other accessible biopsy site

Differential diagnosis. A destructive or marrow-replacing vertebral lesion is not always a carcinoma metastasis. The key differentials and their discriminating features:

Algorithm

View larger

Corticosteroids

Dexamethasone for MESCC is started immediately at presentation:

It works by reducing vasogenic oedema, with a possible tumoricidal effect on lymphoma. Co-prescribe gastric protection, monitor glucose, and taper once definitive treatment is established.

Bone-Modifying Agents

Every patient with solid-tumour bone metastases (and myeloma) should be considered for a bone-modifying agent to reduce skeletal-related events (SREs: pathological fracture, cord compression, need for radiotherapy or surgery to bone, and hypercalcaemia). Both classes require a dental review before starting and calcium plus vitamin D supplementation.

• Bisphosphonates (zoledronic acid) inhibit osteoclast-mediated resorption and reduce SREs across solid tumours and myeloma; they are renally cleared, so avoid or dose-reduce in renal impairment
• Denosumab, a monoclonal RANKL inhibitor given subcutaneously, is at least as effective as zoledronic acid for SRE reduction

Non-Operative Management

Non-operative management is the path when the mechanical and neurological axes are quiet, or when the systemic axis rules surgery out:

• SINS 0-6 (stable)
• Bilsky 0-1b with a radiosensitive tumour
• Poor surgical candidate or short life expectancy, by the systemic criteria above

Conventional RTSBRT

External beam radiation (cEBRT) is effective for radiosensitive tumours and for pain palliation. Three regimens:

• 30 Gy in 10 fractions (standard)
• 20 Gy in 5 fractions (hypofractionated)
• 8 Gy single fraction (palliation)

What it achieves. Pain relief in 70-80%, motor improvement in 40-60%, and local control of 60-70% in radiosensitive tumours. Its limits are the dose constraint near the spinal cord and the radioresistant histologies, where 30-40% have failed locally at 1 year.

Stereotactic body radiotherapy delivers an ablative dose for durable control:

• 24 Gy single fraction
• 27 Gy in 3 fractions
• 30-35 Gy in 5 fractions

What it achieves. Superior local control, 85-95% at 1 year, effectiveness against radioresistant tumours, and a shorter course. The price is geometry: it needs a 2-3mm gap between tumour and cord, so high-grade ESCC needs separation surgery first. Note the RTOG 0631 caveat below: SBRT is about durable tumour control, not better simple pain palliation.

View larger

View larger

Surgical Management

Indications. Surgery is offered when one of six things is true:

1. Mechanical instability (SINS 13-18)
2. High-grade ESCC (Bilsky 2-3) with deficit
3. Radioresistant tumour with Bilsky 1c or higher
4. Progressive deficit despite radiation
5. Pathological fracture with canal compromise
6. Tissue diagnosis needed

Separation surgery. The purpose is to create the 2-3mm gap around the cord that makes high-dose SBRT or SRS safe, not to remove the tumour: a posterior approach with instrumentation and circumferential decompression, not gross total or en bloc resection. Postoperative SBRT typically follows within 2-4 weeks. In the Laufer series 1-year local control was about 84% overall, rising to about 96% with high-dose hypofractionated SRS (24-30 Gy in 3 fractions).

Approach. Posterior is the most common: extensile, and it takes pedicle screws. Anterior gives corpectomy and cervical plating. Minimally invasive options are percutaneous screws and vertebroplasty.

Instrumentation. Fix a minimum of 2 levels above and below the lesion, use cement augmentation in poor bone, and support the anterior column with an expandable cage.

View larger

View larger

View larger

View larger

View larger

Surgical complications run from the general to the spine-specific:

• Wound infection: 5-10%
• DVT/PE: 5-15%
• Medical complications: 10-20%
• 30-day mortality: 5-10%
• Hardware failure: 5-10%
• Adjacent level fracture: 5-15%
• Neurological deterioration: 2-5%
• CSF leak: 2-5%

Wounds are the particular problem after prior radiation, where the risk is higher and plastic surgery may be needed for closure.

Radiation. Acute effects are dermatitis, oesophagitis in the thoracic spine, nausea and fatigue. The late effects are radiation myelopathy, rare with modern techniques, and vertebral compression fracture in 10-15% after SBRT.

Local recurrence at 1 year is the number that separates the treatments:

• cEBRT alone (radioresistant): 30-40%
• SBRT: 5-15%
• Separation surgery + SBRT: about 16% overall, about 4% with high-dose hypofractionated SRS (the Laufer series)

View larger

Global Epidemiology

Spine is the most common site of skeletal metastasis worldwide, and the spine is involved in the majority of patients with bone metastases at autopsy. Roughly 10-30% of cancer patients develop clinically relevant spinal metastases during their disease, and around 5-10% develop metastatic epidural spinal cord compression (MESCC). As cancer survival improves globally with modern systemic therapy, the population living with spinal metastases is growing, increasing demand for spine oncology services. Across high-income health systems the dominant primaries are consistent: in the SCORAD cohort (UK and Australia) prostate (44%), lung (19%) and breast (12%) accounted for most MSCC, mirroring the BPLTK pattern (Hoskin, JAMA 2019, PMID 31794625).

Side-by-Side Guidance

Registry and Trial Evidence

There is no single dominant international spinal-metastasis registry equivalent to arthroplasty registries; the evidence base rests on landmark RCTs (Patchell 2005, SCORAD 2019, RTOG 0631 2023) plus large institutional cohorts (e.g. the Laufer separation-surgery series) and prospective prognostic-score validation (Tokuhashi, Tomita). The Global Spine Tumour Study Group and AO Spine Knowledge Forum Tumour have driven prospective multinational data collection on surgical outcomes, quality of life and prognostic modelling, increasingly favouring patient-reported outcomes over survival alone.

Practice Variation

Real-world practice varies with access to technology and multidisciplinary infrastructure. SBRT/SRS and separation surgery are concentrated in tertiary centres with image-guided radiotherapy and spinal navigation; in lower-resource settings conventional EBRT and posterior decompression-stabilisation remain the mainstay. Timeliness also varies: NICE-style emergency pathways with 24-hour MRI access are not universally available, and delayed diagnosis remains a major determinant of poorer ambulatory outcome globally.

1. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010;35(22):E1221-9. PMID 20562730. doi:10.1097/BRS.0b013e3181e16ae2
2. Fourney DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the Spine Oncology Study Group. J Clin Oncol. 2011;29(22):3072-7. PMID 21709187. doi:10.1200/JCO.2010.34.3897
3. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine. 2010;13(3):324-8. PMID 20809724. doi:10.3171/2010.3.SPINE09459
4. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-8. PMID 16112300. doi:10.1016/S0140-6736(05)66954-1
5. Laufer I, Iorgulescu JB, Chapman T, et al. Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery. J Neurosurg Spine. 2013;18(3):207-14. PMID 23339593. doi:10.3171/2012.11.SPINE12111
6. Ryu S, Deshmukh S, Timmerman RD, et al. Stereotactic radiosurgery vs conventional radiotherapy for localized vertebral metastases of the spine: phase 3 results of NRG Oncology/RTOG 0631 randomized clinical trial. JAMA Oncol. 2023;9(6):800-7. PMID 37079324. doi:10.1001/jamaoncol.2023.0356
7. Hoskin PJ, Hopkins K, Misra V, et al. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322(21):2084-94. PMID 31794625. doi:10.1001/jama.2019.17913
8. Barzilai O, Laufer I, Yamada Y, et al. Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: neurologic, oncologic, mechanical stability, and systemic disease. J Clin Oncol. 2017;35(21):2419-27. PMID 28640703. doi:10.1200/JCO.2017.72.7362
9. Tomita K, Kawahara N, Kobayashi T, et al. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2001;26(3):298-306. PMID 11224867. doi:10.1097/00007632-200102010-00016
10. Tokuhashi Y, Matsuzaki H, Oda H, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 2005;30(19):2186-91. PMID 16205345. doi:10.1097/01.brs.0000180401.06919.a5